Cause Style 1 – Sidebar

‘Dare2Cure’ Public Symposium on Recent Advances in Lung Cancer with Prof Ken O’Byrne

In person and livestreamed. The Cancer Clinical Research Trust together with The Caroline Foundation hosts a ‘Dare2Cure’ Public symposium on Recent Advances in Lung Cancer with Guest Speaker, Professor Ken O’ Byrne, Professor of Medical Oncology, Princess Alexandra Hospital, Queensland University of Technology, Translational Research Institute Queensland Senior Clinical Research Fellow on Wednesday September 27th 2023 from 6.30-7.30pm at The Herbert Park Hotel, Ballsbridge, Dublin 4. The symposium will be chaired by Professor John Crown.

To register to attend IN PERSON for the symposium click here  

To view the LIVESTREAM of the talk please click on the following link at 6pm on Wednesday September 28th: Link to livestream

The 16th International Symposium on Translational Research in Oncology, Sept 27th-29th, 2023, Herbert Park Hotel, Dublin 4

To Register for the 16th International Symposium on Translational Research in Oncology please click here

For printable version of programme please click here: 18.09.23 Programme – 16th International Symposium on Translational Research in Oncology

To register for the AICRI – Vision and Showcase event click here

16th International Symposium on Translational Research in Oncology


Wednesday, 27th September 2023, Lansdowne Suite 

09.00 – 12.30 AICRI Showcase To register for the AICRI showcase click here

Registration for the Symposium from 12:30                                CPD:3 external credits

13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s Hospital Group, Dublin

TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center

13:45 – 14:15 HER2 as a therapeutic target in HER2-normal breast cancer

Prof. Sara Hurvitz, Senior Vice President, Clinical Research Division, Fred Hutchinson Cancer Center, Head, Division of Hematology/Oncology, University of Washington

14:15 – 14:45 Targeting Estrogen Receptor in breast cancer: old target, new drugs

Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston

14:45 – 15:15 HER2+ GP2 vaccine and the FLAMINGO Phase III trial

Mr. Snehal Patel, CEO, Greenwich Lifesciences

15:15 – 15:30 Coffee break

TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center

15:30 – 16:15 Patient-derived models of breast cancer for drug discovery and precision medicine

Dr. Alana Welm, Huntsman Cancer Institute, University of Utah, Salt Lake City

16:15 – 16:45 TPD squared – Dual-Precision Targeted Protein Degradation For Oncology Therapeutics Discovery and Development

Dr. James Palacino, VP/Head of Biology, Orum Therapeutics


16:45 – 17:15 Topic: CDK inhibitors and the NATALEE trial

Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology UCLA.


Thursday, 28th September 2023, Lansdowne Suite, Herbert Park Hotel

Registration from 08:30                                                     CPD:  6 external credits

TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto

09:00 – 09:30 Modulation of the tumor associated fibronectin ECM to enhance efficacy of immune checkpoint blockade

Prof Robert Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute, University of Toronto

09:30 – 10:00 Overcoming endothelial cell anergy for improvement of immunotherapy against cancer

Prof Arjan Griffioen, Head of the Angiogenesis Laboratory, Amsterdam UMC

10:00 – 10:30 Orally available RGD-mimetic and enhancement of immunotherapy efficacy

Prof Kairbaan Hodivala Dilke, Professor of Tumour Microenvironment, Queen Mary University of London, and Deputy Director of Barts Cancer Institute.

10:30 – 10:45        Coffee break

TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto

10:45 – 11:15 Brain metastasis in the era of immunotherapy: implications for sequential immunotherapy-based combination therapy

Prof Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center

 11.15 – 11:45 Control of malignant properties by functionally and spatially distinct cancer-associated fibroblasts

Professor Kristian Pietras, Division of Translational Cancer Research, Lund University Cancer Centre

11:45 – 12:15    Extracellular Vesicles in the Tumour Microenvironment

Prof Lorraine O’Driscoll, School of Pharmacy & Pharmaceutical Sciences, Panoz Institute & Trinity Biomedical Sciences Institute & Research Director, Trinity St. James’s Cancer Institute, Trinity College Dublin


12:15 – 13:00    Normalizing the tumor microenvironment to improve immunotherapy of brain tumors: Emerging insights and strategies

Prof. Rakesh Jain, National Medal of Science Awardee 2013, Andrew Werk Cook Professor of Tumor Biology, Massachusetts General Hospital, Harvard Medical School & Director E.L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital.

13:00 – 14:00   Lunch

Targeting Difficult to Drug Genes for Cancer Therapy: Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin

14:00 – 14:30 Targeting MYC: A Dual Effect on Both Cancer Cells and Tumor Microenvironment

Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.

14:30 – 15:00   Biomarker driven development of Brigimadlin, a MDM2-p53 antagonist restoring p53 activity

Dr. Michael Teufel, Exec Dir Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim

15:00 – 15:30    Combination strategies to potentiate the impact of KRAS inhibitors

Dr. Miriam Molina-Arcas, Oncogene Biology Laboratory, The Francis Crick Institute

15:30 – 15:45  Coffee break

Novel Targeted therapies: Session Chair – Prof Denis Collins, Dublin City University

15:45 – 16.15        Development of a novel therapeutic mAb and ADC for CLDN18.2

Dr. Neil O’Brien, Adj Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA

16:15 – 16:45        Selective Therapies for Metastatic Tumor Cells

Prof Bruce Zetter, Charles Nowiszewski Professor of Cancer Biology, Harvard

16:45 – 17:15  Evolving insights into biomarkers and treatment of hepatocellular carcinoma

Prof. Richard Finn, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.

17:15 – 17:45   Development and characterisation of an anti-Claudin-6 (CLDN6) ADC for the treatment of CLDN6 positive cancer

Dr. Martina McDermott, Adj Assoc Prof, Dept of Medicine, Division of Hematology/Oncology, UCLA ______________________________________________________________

Friday 29th September 2023, Lansdowne Suite, Herbert Park Hotel

Registration from 8:30                                                              CPD:  4 external credits

CANCER IMMUNOTHERAPY I – exploiting immune cells: Session Chair – Prof. Mario Sznol, Yale

09:00 – 09:30       DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates anti-tumor immunity

Dr. Michael Dougan, Massachusetts General Hospital, Harvard Medical School

09:30 – 10:00     Novel Biomarker Discovery for NX-1607: Clinical Insights into a First-in-Class Oral CBL-B Inhibitor for Advanced Malignancies

Dr. Sarah Whelan, Associate Director, Translational Medicine, Nurix Therapeutics   

10:00 – 10:30 ACTengine® IMA203 TCR-T: Unleashing the Potential of Targeting PRAME in Solid Tumors

Prof. Dr. med Oliver Ebert, Senior Director, Head of Clinical Development, Immatics

10:30 – 11:00       Cancer cell metabolomics and immunotherapy resistance

Prof.  Ken O’ Bryne, Professor of Medical Oncology, Queensland University of Technology

11:00 – 11:15       Coffee break

CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale

11:15-11:45   Cis-targeting of IL-2 and IL-21 cytokines to CD8+ T cells to improve immunotherapies for cancer

Dr. Ivana Djuretic, Chief Scientific Officer, Asher Biotherapeutics

11:45 – 12:15     Development of XTX301, a bioengineered masked, tumor-activated IL-12: unleashing the potent cytokine in the tumor microenvironment

Dr. Katarina Luptakova, MD, Senior Vice President, Medical, Xilio Therapeutics

12:15 – 12:45        New Strategies in Immuno-Oncology: Tumor-directed Oncolytic Immunotherapy (TOI)

Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune

12:45 – 13:00  Q & A

13:00 – 14:00     Lunch

Novel targeted drugs & biomarkers: Session Chair – Prof William Gallagher, University College Dublin

14:00 – 14:30   Cancer as a combinatorial challenge

Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program

14:30 – 15:00     Targeting mediator kinases in prostate and breast cancers

Prof Igor Roninson, CSO, Senex Biotechnology & Prof Eugenia Broude, University of South Carolina

15:00 – 15:30      The role of MRD detection and quantitation in solid tumors

Dr Minetta Liu, Chief Medical Officer, Natera

15:30 – 15:45       Coffee break

Novel targeted drugs & biomarkers II: Session Chair – Prof John Crown, St Vincent’s Hospital

15:45 – 16:15    Understanding TIL therapy for metastatic melanoma

Prof John Haanen, Medical Oncology Dept. Netherlands Cancer Institute

16:15 – 16:45    A Phase 1/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 in Patients with Advanced HER2-Expressing Solid Tumors (NCT04278144)

Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine

16:45 – 17:15  Topic: Fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma

Prof. John Crown, Consultant Medical Oncologist, St Vincent’s Hospital, Dublin; Professor of Oncology, University College Dublin; Thomas Baldwin Chair of Translational Oncology, Dublin City University

                         Meeting Ends


First-in-world, Caroline-1 clinical trial, will commence this month at St. Vincent’s University Hospital under the leadership of Professor John Crown

As a result of many years of collaborative research by CCRT and The Caroline Foundation funded researchers based in the NICB in DCU we are delighted to announce that, as a result of this research, the first-in-world, Caroline-1 clinical trial, will commence this month at St. Vincent’s University Hospital under the leadership of Professor John Crown. Please see the press release below for further information.


A new drug combination to treat women with metastatic HER2-positive breast cancer that is based on prior preclinical studies from Dublin City University will enter clinical development in a Phase 1 clinical trial named CAROLINE-1, which will commence later this month.

Researchers at DCU’s National Institute for Cellular Biotechnology (NICB) have previously demonstrated the benefit of combining neratinib, an irreversible pan-HER kinase inhibitor, with standard HER2 antibody therapies, trastuzumab and pertuzumab, in laboratory models. This work has been carried out in collaboration with Puma Biotechnology, Inc., a U.S.-based biopharmaceutical company.

Ireland will become the first country to assess the new combination in women with metastatic HER2-positive breast cancer. The aim of the investigation is to improve on the response currently achieved with standard treatments.

HER2-positive breast cancer accounts for approximately 560 of the 2,500 new breast cancer cases diagnosed in Ireland each year.  About 15% of these patients will develop metastatic disease. While the treatment options for patients where this disease has spread are successful for some, for many patients the disease returns. The Caroline-1 study is the first step in the development of a new combination for those patients. The focus of the Phase 1 clinical trial is to confirm the treatment is safe and tolerable and, once this is shown, a Phase 2 clinical trial will look closely at the ability of the new combination to successfully control this cancer.

Explaining the background to the breakthrough, Dr. Denis Collins said,

“This development has been a truly translational process and is the culmination of many years’ work by researchers based in the NICB, most notably Dr. Norma O’Donovan and funders Cancer Clinical Research Trust, The Caroline Foundation and BreastPredict. We found that adding neratinib to existing HER2 antibody therapies improved the anti-cancer effect in the laboratory setting and this provided a compelling rationale for examination in the clinic.”

The CAROLINE-1 study is sponsored by Puma Biotechnology, Inc. and led by Professor John Crown of St. Vincent’s University Hospital, who was recently re-appointed as the Thomas Baldwin Chair of Translational Medicine at DCU.

Commenting on the upcoming clinical trial, Professor Crown said,

“This Phase 1 clinical trial will be conducted in women who have metastatic HER2-positive breast cancer.  Whilst women with this disease usually respond well initially to treatment, their response is typically not permanent and the disease will likely return.  We hope that this drug combination will prolong the time until a women’s disease returns.

“This is an exciting accomplishment, as the trial is based on the work we conducted in our lab at DCU,” added Professor Crown. “We have worked with Puma Biotechnology, Clinical Oncology Development Europe and Saint Vincent’s University Hospital to bring the first-in-world CAROLINE-1 study to Ireland.

CAROLINE-1 is named for Caroline Dwyer-Hickey who tragically passed away as a result of metastatic breast cancer. The Caroline Foundation was set up in her honour and supports the laboratory work at DCU, which has led to this trial. Our hope is that this trial will improve the treatment options available to women with metastatic HER2-positive breast cancer.”